MA53268A - Mini-gde pour le traitement de la maladie de stockage du glycogène iii - Google Patents
Mini-gde pour le traitement de la maladie de stockage du glycogène iiiInfo
- Publication number
- MA53268A MA53268A MA053268A MA53268A MA53268A MA 53268 A MA53268 A MA 53268A MA 053268 A MA053268 A MA 053268A MA 53268 A MA53268 A MA 53268A MA 53268 A MA53268 A MA 53268A
- Authority
- MA
- Morocco
- Prior art keywords
- edg
- glycogen
- mini
- treatment
- storage disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
- C12N9/1055—Levansucrase (2.4.1.10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2451—Glucanases acting on alpha-1,6-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01025—4-Alpha-glucanotransferase (2.4.1.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01033—Amylo-alpha-1,6-glucosidase (3.2.1.33)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306088 | 2018-08-08 | ||
| PCT/EP2019/071158 WO2020030661A1 (fr) | 2018-08-08 | 2019-08-06 | Mini-gde pour le traitement de la maladie de stockage du glycogène iii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53268A true MA53268A (fr) | 2021-11-17 |
| MA53268B1 MA53268B1 (fr) | 2023-06-28 |
Family
ID=63311942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53268A MA53268B1 (fr) | 2018-08-08 | 2019-08-06 | Mini-gde pour le traitement de maladies de stockage de glycogène de type iii |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210292724A1 (fr) |
| EP (2) | EP3833746B1 (fr) |
| JP (2) | JP2021532810A (fr) |
| KR (1) | KR20210053902A (fr) |
| CN (1) | CN112654698A (fr) |
| AU (1) | AU2019317754A1 (fr) |
| BR (1) | BR112021002202A2 (fr) |
| CA (1) | CA3107572A1 (fr) |
| DK (1) | DK3833746T3 (fr) |
| EA (1) | EA202190475A1 (fr) |
| ES (1) | ES2946415T3 (fr) |
| FI (1) | FI3833746T3 (fr) |
| IL (1) | IL280570A (fr) |
| MA (1) | MA53268B1 (fr) |
| PL (1) | PL3833746T3 (fr) |
| PT (1) | PT3833746T (fr) |
| WO (1) | WO2020030661A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000003371A1 (it) * | 2020-02-19 | 2021-08-19 | Enea Agenzia Naz Per Le Nuove Tecnologie Lenergia E Lo Sviluppo Economico Sostenibile | Composto per il trattamento di una glicogenosi |
| WO2022023284A1 (fr) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions de molécules d'adn, leurs procédés de fabrication et leurs procédés d'utilisation |
| EP4200410A1 (fr) | 2020-08-24 | 2023-06-28 | Genethon | Gde tronqué à terminaison c pour le traitement de la glycogénose iii |
| KR20240012370A (ko) | 2021-04-20 | 2024-01-29 | 안자리움 바이오사이언시스 아게 | 아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법 |
| WO2023237731A1 (fr) | 2022-06-09 | 2023-12-14 | Genethon | Gde tronquée au niveau du terminal n pour le traitement de la maladie de stockage du glycogène de type iii |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030157064A1 (en) | 2001-11-09 | 2003-08-21 | Pascal Neuville | Chimeric promoters for controlling expression in muscle cells |
| ES2647477T3 (es) | 2004-06-01 | 2017-12-21 | Genzyme Corporation | Composiciones y métodos para prevenir la agregación del vector AAV |
| EP3586868B1 (fr) | 2008-04-22 | 2023-11-08 | Vib Vzw | Éléments régulateurs d'acides nucléiques spécifiques au foie et procédés et leur utilisation |
| US20160089451A1 (en) * | 2013-02-20 | 2016-03-31 | Dustin D. Armstrong | Methods and compositions for treatment of forbes-cori disease |
| KR102380265B1 (ko) | 2013-07-22 | 2022-03-29 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
| JP6626829B2 (ja) | 2014-01-21 | 2019-12-25 | フレイエ ユニヴェルシテイト ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｂｒｕｓｓｅｌ | 筋特異的核酸調節エレメント並びにその方法及び使用 |
| CA2942451A1 (fr) | 2014-04-25 | 2015-10-29 | Genethon | Traitement de l'hyperbilirubinemie |
| CN107636153B (zh) * | 2014-12-23 | 2020-12-11 | 美国政府(由卫生和人类服务部的部长所代表) | 编码经修饰的g6pc的腺相关病毒载体及其用途 |
-
2019
- 2019-08-06 CA CA3107572A patent/CA3107572A1/fr active Pending
- 2019-08-06 PL PL19746522.2T patent/PL3833746T3/pl unknown
- 2019-08-06 WO PCT/EP2019/071158 patent/WO2020030661A1/fr unknown
- 2019-08-06 US US17/265,528 patent/US20210292724A1/en active Pending
- 2019-08-06 MA MA53268A patent/MA53268B1/fr unknown
- 2019-08-06 CN CN201980052158.4A patent/CN112654698A/zh active Pending
- 2019-08-06 FI FIEP19746522.2T patent/FI3833746T3/fi active
- 2019-08-06 DK DK19746522.2T patent/DK3833746T3/da active
- 2019-08-06 JP JP2021506450A patent/JP2021532810A/ja active Pending
- 2019-08-06 EA EA202190475A patent/EA202190475A1/ru unknown
- 2019-08-06 EP EP19746522.2A patent/EP3833746B1/fr active Active
- 2019-08-06 PT PT197465222T patent/PT3833746T/pt unknown
- 2019-08-06 KR KR1020217006722A patent/KR20210053902A/ko active Search and Examination
- 2019-08-06 BR BR112021002202-3A patent/BR112021002202A2/pt unknown
- 2019-08-06 ES ES19746522T patent/ES2946415T3/es active Active
- 2019-08-06 AU AU2019317754A patent/AU2019317754A1/en active Pending
- 2019-08-06 EP EP23163233.2A patent/EP4230733A1/fr active Pending
-
2021
- 2021-02-01 IL IL280570A patent/IL280570A/en unknown
-
2024
- 2024-02-26 JP JP2024026467A patent/JP2024054398A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4230733A1 (fr) | 2023-08-23 |
| JP2024054398A (ja) | 2024-04-16 |
| DK3833746T3 (da) | 2023-05-30 |
| MA53268B1 (fr) | 2023-06-28 |
| IL280570A (en) | 2021-03-25 |
| JP2021532810A (ja) | 2021-12-02 |
| KR20210053902A (ko) | 2021-05-12 |
| ES2946415T3 (es) | 2023-07-18 |
| EP3833746B1 (fr) | 2023-03-29 |
| CN112654698A (zh) | 2021-04-13 |
| BR112021002202A2 (pt) | 2021-05-04 |
| WO2020030661A1 (fr) | 2020-02-13 |
| US20210292724A1 (en) | 2021-09-23 |
| FI3833746T3 (fi) | 2023-06-01 |
| EP3833746A1 (fr) | 2021-06-16 |
| PT3833746T (pt) | 2023-05-25 |
| PL3833746T3 (pl) | 2023-12-04 |
| CA3107572A1 (fr) | 2020-02-13 |
| AU2019317754A1 (en) | 2021-02-18 |
| EA202190475A1 (ru) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53268A (fr) | Mini-gde pour le traitement de la maladie de stockage du glycogène iii | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA53661A (fr) | Agonistes du récepteur farnésoïde x pour le traitement d'une maladie | |
| MA45052A (fr) | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille | |
| MA50578A (fr) | Systèmes crispr/cas pour le traitement de dmd | |
| FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| IL277217A (en) | Use of anti-IL-36R antibodies to treat inflammatory bowel disease | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
| MA53501A (fr) | Inhibiteurs de pde9 pour le traitement de la drépanocytose | |
| MA49131A (fr) | Utilisation d'antagonistes de klk5 pour le traitement d'une maladie | |
| MA54544A (fr) | Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA47395A (fr) | Méthode pour le traitement d'une maladie neurologique | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA46086A (fr) | Schéma posologique pour le traitement de tumeurs solides | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| MA47776A (fr) | Polythérapies pour le traitement du cancer du sein |